Helius Medical Ownership
| HSDT Stock | USD 0.49 0.03 6.52% |
Shares in Circulation | First Issued 2013-06-30 | Previous Quarter 2.5 M | Current Value 3.7 M | Avarage Shares Outstanding 697.8 K | Quarterly Volatility 2.9 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Helius |
Helius Stock Ownership Analysis
The company has price-to-book (P/B) ratio of 0.45. Some equities with similar Price to Book (P/B) outperform the market in the long run. Helius Medical Techn recorded a loss per share of 4.27. The entity last dividend was issued on the 4th of January 2021. The firm had 1:50 split on the 17th of August 2023. Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator , is a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. Helius Medical operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 19 people. To learn more about Helius Medical Technologies call Dane Andreeff at 215 944 6100 or check out https://heliusmedical.com.Helius Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Helius Medical is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Helius Medical Technologies backward and forwards among themselves. Helius Medical's institutional investor refers to the entity that pools money to purchase Helius Medical's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | St Germain D J Co Inc | 2024-09-30 | 2.0 | Wells Fargo & Co | 2024-06-30 | 0.0 | Armistice Capital, Llc | 2024-09-30 | 0.0 | Geode Capital Management, Llc | 2024-09-30 | 17.8 K | Susquehanna International Group, Llp | 2024-06-30 | 16.3 K | Vanguard Group Inc | 2024-09-30 | 12.6 K | Tower Research Capital Llc | 2024-06-30 | 6.9 K | Ubs Group Ag | 2024-06-30 | 1.5 K | Corecap Advisors, Llc | 2024-06-30 | 200 | Advisor Group Holdings, Inc. | 2024-06-30 | 80.0 | Federation Des Caisses Desjardins Du Quebec | 2024-06-30 | 37.0 |
Helius Medical Techn Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Helius Medical insiders, such as employees or executives, is commonly permitted as long as it does not rely on Helius Medical's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Helius Medical insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buckman Paul over three months ago Acquisition by Buckman Paul of 31000 shares of Helius Medical at 0.965 subject to Rule 16b-3 | ||
Favit-van Pelt Antonella R. over three months ago Acquisition by Favit-van Pelt Antonella R. of 277000 shares of Helius Medical at 0.965 subject to Rule 16b-3 | ||
Dane Andreeff over three months ago Acquisition by Dane Andreeff of 808000 shares of Helius Medical at 0.965 subject to Rule 16b-3 | ||
Perkins Sherrie L over a year ago Acquisition by Perkins Sherrie L of 83054 shares of Helius Medical subject to Rule 16b-3 | ||
Mathiesen Jeffrey S over a year ago Acquisition by Mathiesen Jeffrey S of 2693000 shares of Helius Medical subject to Rule 16b-3 |
Helius Medical Outstanding Bonds
Helius Medical issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Helius Medical Techn uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Helius bonds can be classified according to their maturity, which is the date when Helius Medical Technologies has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| US42329HAA68 Corp BondUS42329HAA68 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Helius Stock Analysis
When running Helius Medical's price analysis, check to measure Helius Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Helius Medical is operating at the current time. Most of Helius Medical's value examination focuses on studying past and present price action to predict the probability of Helius Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Helius Medical's price. Additionally, you may evaluate how the addition of Helius Medical to your portfolios can decrease your overall portfolio volatility.